Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P42126

UPID:
ECI1_HUMAN

ALTERNATIVE NAMES:
3,2-trans-enoyl-CoA isomerase; Delta(3),Delta(2)-enoyl-CoA isomerase; Dodecenoyl-CoA isomerase

ALTERNATIVE UPACC:
P42126; A8K512; Q13290; Q7Z2L6; Q7Z2L7; Q9BUB8; Q9BW05; Q9UDG6

BACKGROUND:
The enzyme Enoyl-CoA delta isomerase 1, located in mitochondria, and known alternatively as Delta(3),Delta(2)-enoyl-CoA isomerase or Dodecenoyl-CoA isomerase, is essential for converting 3-cis and 3-trans double bonds into the 2-trans configuration in various enoyl-CoA molecules. This action is critical for the efficient beta-oxidation of fatty acids, a major cellular pathway for energy production from fats.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Enoyl-CoA delta isomerase 1 offers a promising avenue for developing new treatments. Given its central role in metabolizing fatty acids, targeting this enzyme could lead to innovative therapies for metabolic diseases characterized by abnormal lipid accumulation or defective energy metabolism.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.